Positive early data from the BRIDGE1 study, a three-year 1000+ patient study in bronchiectasis funded by the British Lung Foundation (BLF) …
Type and hit ENTER
Jason Siegel
ProAxsis Limited (www.proaxsis.com) today announces that it has successfully registered a CE Mark for its ProteaseTag® Active Plasmin Immunoassay. This novel technology …
January 8, 2018
Posted by Webmaster
ProAxsis’ ProteaseTag® technology will again be featured at the Winter meeting of the British Thoracic Society, which takes place between December 6th-8th at …
December 5, 2017
Posted by Webmaster
Having reached the first anniversary following relocation to its new purpose-built laboratory on the Catalyst Inc. site in the Titanic Quarter of …
November 21, 2017
Posted by Webmaster
ProAxsis will be presenting further data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference, which takes place between …
October 30, 2017
Posted by Webmaster
ProAxsis Limited has contracted with National Jewish Health (NJH), the leading respiratory hospital in the United States, to validate the company’s …
October 27, 2017
Posted by Webmaster
ProAxsis today announces that the company has appointed Diagenics Limited as the distributor for its ProteaseTag® Active Neutrophil Elastase Immunoassay in Great …
September 14, 2017
Posted by Webmaster
ProAxsis Ltd today announces that the company has signed a partnership agreement to develop activity-based immunoassays for two key respiratory proteases, …
September 11, 2017
Posted by Webmaster
ProAxsis will be presenting further data on its ProteaseTag® technology, at the European Respiratory Society Conference, which takes place between September 9th-13thin …
September 6, 2017
Posted by Webmaster
ProAxsis Ltd today announces that the company has completed the development process for NEATstik®, a novel point-of-care test for measuring active …
September 4, 2017
Posted by Webmaster
Following its previous success in the BioMedical Catalyst competition, ProAxsis Limited (www.proaxsis.com) has now gained further support for its ProteaseTag® technology, via …
July 24, 2017
Posted by Webmaster
ProAxsis was delighted to see its ProteaseTag® technology incorporated in to an important study presented at the European Cystic Fibrosis Society …
June 19, 2017
Posted by Webmaster
Dr David Ribeiro, CEO of ProAxsis, will be attending the Anglonordic Life Sciences Conference, taking place in London this week, and will …
May 30, 2017
Posted by Webmaster
ProAxsis Ltd is delighted to observe that its ProteaseTag® Active Neutrophil Elastase Immunoassay is prominently featured in the most recent edition of …
May 17, 2017
Posted by Webmaster
ProAxsis Limited (www.proaxsis.com) is delighted to announce that it has secured a second licensing agreement with the Queen’s University of Belfast for …
May 10, 2017
Posted by Webmaster
ProAxsis will be presenting further data on its ProteaseTag® technology, at the American Thoracic Society Conference, which takes place between May 19th-24th …
May 5, 2017
Posted by Webmaster
Dr David Ribeiro, CEO of ProAxsis, will be attending the Bio-Europe Spring meeting, taking place in Barcelona on March 20th-22nd 2017, and will …
March 6, 2017
Posted by Webmaster
ProAxsis Limited (www.proaxsis.com) is further expanding its ProteaseTag® technology platform, via a project co-funded by the UK’s innovation agency, Innovate UK. ProAxsis …
January 25, 2017
Posted by Webmaster
In a significant new study, a team at the University of Dundee has shown for the first time that sputum neutrophil elastase (NE) activity, …
December 23, 2016
Posted by Webmaster
ProAxsis (www.proaxsis.com) was delighted to observe that measuring active neutrophil elastase (NE) by its ProteaseTag® Active NE Immunoassay was identified as a …
December 8, 2016
Posted by Webmaster
ProAxsis will this week be presenting new data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference in Orlando, Florida. The …
October 26, 2016
Posted by Webmaster
ProAxsis were this week delighted to host His Royal Highness, the Duke of York, at their new laboratory facilities within the Concourse …
October 19, 2016
Posted by Webmaster
ProAxsis Limited (www.proaxsis.com) is pleased to announce that it has successfully registered a CE Mark for its novel ProteaseTag® Active Neutrophil Elastase …
September 30, 2016
Posted by Webmaster
Dr David Ribeiro, CEO of ProAxsis, will be attending the 16th Biotech in Europe Forum, taking place in Basel on September 27th-28th 2016, …
September 23, 2016
Posted by Webmaster
ProAxsis (www.proaxsis.com) is delighted to have been featured in the latest edition of Business Eye, Northern Ireland’s premium business magazine. This article …
September 16, 2016
Posted by Webmaster
ProAxsis (www.proaxsis.com) is undertaking business development activities with Invest Northern Ireland support. Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, …
June 20, 2016
Posted by Webmaster
ProAxsis will be attending the BIO 2016 conference, taking place at the Moscone Convention Center in San Francisco between June 5th-9th 2016. The …
June 2, 2016
Posted by Webmaster
ProAxsis will this week be presenting further data on its ProteaseTag® Active Neutrophil Elastase (NE) Immunoassay, at the American Thoracic Society Conference in …
May 16, 2016
Posted by Webmaster
ProAxsis is delighted to announce that Dr Kelly Moffitt has joined the company in the role of Senior Project Manager, and will …
May 9, 2016
Posted by Webmaster
ProAxsis CEO David Ribeiro was interviewed by ProActive Investors UK. Watch the video on Stock-Tube
May 4, 2016
Posted by Webmaster
ProAxsis is pleased to announce the appointment of Sarah Ganniclefft to the newly created role of Sales and Marketing Manager. Sarah …
April 20, 2016
Posted by Webmaster
Dr David Ribeiro, CEO of ProAxsis, will be attending the 10th anniversary Biotrinity conference, taking place in London on April 25th-27th 2016, and …
April 19, 2016
Posted by Webmaster
ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland
tel +44 (0)28 9073 0444
email info@proaxsis.com
RECENT NEWS
-
July 9, 2020
ProAxsis and the Connected Health Innovation Centre launch new partnership
-
June 29, 2020
ProAxsis and Ulster University initiate new partnership
-
June 23, 2020
ProAxsis announces new appointments
LATEST TWEETS
ProAxsis
@ProAxsis are delighted to announce our collaboration with @UlsterUni and look forward to enhancing our portfolio o… https://t.co/MJW52m0590
9 days ago - ProAxsisRT @dundeeuni: A drug which potentially reduces the risk of people living with a chronic lung disease from needing antibiotics or emergency…
13 days ago - ProAxsisRT @AlfahlZina: A great presentation by @ProfJDChalmers on the new DPP1 inhibitor therapy in Bronchiectasis at the ATS conference @atscommu…
14 days ago - ProAxsisRT @lungscotland: Great to see British Lung Foundation's respiratory research chair, @ProfJDChalmers leading this #COVID_19 clinical trial…
76 days ago - ProAxsisCopyright © 2016-2018 - ProAxsis - All rights reserved.
Webmaster, Author at ProAxsis